Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Swedish Orphan Biovitrum and Biogen Idec announce positive efficacy and safety results from phase-3 paediatric study of investigational therapy Eloctate for haemophilia A


Thursday, 10 Apr 2014 07:04am EDT 

Swedish Orphan Biovitrum publ AB:Says the company and Biogen Idec have released positive results of the Kids A-LONG Phase 3 clinical study.The study evaluated the safety and efficacy of Eloctate, an investigational recombinant factor VIII Fc fusion protein product candidate, in children with severe haemophilia A.Eloctate was generally well-tolerated and no inhibitors were detected.Efficacy analyses showed twice-weekly prophylactic dosing with Eloctate maintained low bleeding rates in children. 

Related Company News

Company Quote

77.0
-1.15 -1.47%
10:34am EST